Scientific misconduct in a breast-cancer chemotherapy trial: Response of University of the Witwatersrand

Lancet

Volumn 355, Issue 9208, 2000, Pages 1011-1012

  Cleaton Jones, P ^a  

^a UNIVERSITY OF THE WITWATERSRAND   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT;

BREAST CANCER; CLINICAL TRIAL; LETTER; MEDICAL ETHICS; MEDICAL RESEARCH; PRIORITY JOURNAL;

EID: 0034681724     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)90003-5     Document Type: Letter

References (4)

1. South African Medical Research Council. Guidelines on ethics for medical research; revised edition. Tygerberg: SAMRC, 1993. Available on http://www.mrc.ac.za/Ethics/ethics.htm (accessed March 8, 2000.
2. Committee for Research on Human Subjects (Medical) of the University of the Wiwatersrand. Available on http://www.wits.ac.za/research/ethics.htm (accessed March 8, 2000).
3. WR Bezwoda. Randomised, controlled trial of high dose chemotherapy (HD-CNVp) versus standard dose (CAF) chemotherapy for high risk, surgically treated, primary breast cancer. Available on http://www.conference-cast.com/asco/abstract_frame.htm (accessed March 8, 2000).
4. S Lock Wells F Fraud and misconduct in medical research 1993 BMJ Publishing Group London